Performance and Safety of Silicone Hydrogel Soft Contact Lenses

Not Applicable

• Conditions: Myopia
• Interventions: Device: ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens; Device: 41% Silicone Hydrogel Soft Contact Lenses(SHSCL); Other: Contact Lens Care Product; Other: Contact Lens Case

• Registration Number: NCT04226560
• Lead Sponsor: ApexLens Co., Ltd.

Brief Summary

To demonstrate substantial equivalence of the new Silicone Hydrogel Soft Contact Lenses(SHSCL) to the commercially available ACUVUE® VITA™ contact lens

Detailed Description

This study is a prospective, subject-masked, bilateral, randomized, parallel group dispensing study comparing the SHSCL test lens against the 1-Month ACUVUE® VITA™ (1-MAV) control lenses. Each subject will be randomized to wear either the test or of the control with similar/comparable lens parameters optimized for vision.

Both test and control lens will be used in their daily wear, monthly replacement modality for thirteen (13) weeks. It is anticipated that this study will involve up to 6 scheduled visits.

Study Timeline

• Study First Submitted: 2020-01-02
• Study First Submitted QC: 2020-01-09
• Study First Posted: 2020-01-13
• Study Start: 2020-04-20
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-23
• Last Update Posted: 2021-02-24
• Primary Completion: 2021-05-30
• Study Completion: 2021-05-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

A person is eligible for inclusion in the study if he/she:

1. Healthy adult males or females age ≥20-45 years of age;
2. Be a currently adapted soft contact lens wearer (i.e. be wearing lenses at least 1 month prior to enrolment) and the last contact lenses worn more than a week ago;
3. Have a contact lens powers between -2.00D and -6.00D (both inclusive) in both eyes;
4. Astigmatism of 1.00D or less in both eyes;
5. Be able to wear the lens powers available for this study;
6. Be correctable to a visual acuity of 0.8 decimal (+0.10 logMAR) or better in each eye;
7. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol;
8. The subject must read and sign the Informed Consent form.

Exclusion Criteria

A person will be excluded from the study if he/she:

1. Previously unsuccessful with contact lens wear, worn rigid gas permeable contact lenses within past 12 months;
2. Women who are pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit);
3. Any ocular or systemic allergies or diseases that may contraindicate contact lens wear;
4. Any ocular medications use within the last one month;
5. Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear;
6. Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV), by self-report;
7. Any current or previous orthokeratology treatment, or planned for orthokeratology treatment during the study;
8. Any previous history of ocular and/or refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.), or planned for ocular and/or refractive surgery during the study
9. History of herpetic keratitis;
10. History of binocular vision abnormality or strabismus, by self-report;
11. Allergic reactions to test lens, control lens or the contact lens solution used in this study;
12. A clinical finding or history of entropion, ectropion, chalazia, recurrent styes, glaucoma, pathologically dry eye, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion, by self-report;
13. Employee of investigational clinic (e.g., Investigator, Coordinator, Technician);
14. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment;
15. Any slit lamp findings which would contraindicate contact lens wear;
16. Any history of a contact lens-related corneal inflammatory event within the past 12 months that may contraindicate contact lens wear; or
17. Clinically significant (grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures;
18. Subjects are considered ineligible for the study as judged by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ACUVUE® VITA™	Contact Lens Case	Healthy adult males or females age ≥20-45 years of age
ACUVUE® VITA™	ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens	Healthy adult males or females age ≥20-45 years of age
41% Silicone hydrogel Soft contact lenses (SHSCL)	41% Silicone Hydrogel Soft Contact Lenses(SHSCL)	Healthy adult males or females age ≥20-45 years of age
41% Silicone hydrogel Soft contact lenses (SHSCL)	Contact Lens Care Product	Healthy adult males or females age ≥20-45 years of age
41% Silicone hydrogel Soft contact lenses (SHSCL)	Contact Lens Case	Healthy adult males or females age ≥20-45 years of age
ACUVUE® VITA™	Contact Lens Care Product	Healthy adult males or females age ≥20-45 years of age

Primary Outcome Measures

Name	Time	Method
Permanent loss of visual acuity	13 weeks	The primary safety endpoint in this evaluation is the percentage of subjects with permanent loss of two or more lines of visual acuity.
Serious adverse reactions	13 weeks	The primary safety endpoint in this evaluation is the rate of serious adverse reactions related to visual acuity loss as well as accompanying slit-lamp findings and other associated observations.
Best-corrected contact lens visual acuity	13 weeks	The primary efficacy endpoint in this evaluation is the percentage of subjects with best-corrected contact lens visual acuity of 0.8 decimal (+0.10 logMAR) and 1.0 decimal (0.00 logMAR) or better.; The Snellen chart will be used for visual acuity testing.

Secondary Outcome Measures

Name	Time	Method
Lens comfort	13 weeks	The secondary efficacy endpoint is the assessment of lens comfort over time with the lens for the recommended wearing time. This will be measured using Study Diary.; Subject will be given a Study Diary to be completed at home, to reflect their lens wear experience at the time of rating. Subject will be given careful explanation of how and when to complete them.; Comfort after insertion (i.e. after lens settling), after 4 hours, and just before lens removal (0-10 scale)(10 = cannot be felt, 0 = painful)
Symptoms of dryness	13 weeks	The secondary efficacy endpoint is the assessment of dryness symptoms with the lens for the recommended wearing time. This will be measured using Study Diary.; Subject will be given a Study Diary to be completed at home, to reflect their lens wear experience at the time of rating. Subject will be given careful explanation of how and when to complete them.; Dryness after insertion (i.e. after lens settling), after 4 hours, and just before lens removal (0-10 scale)(10 = cannot be felt, 0 = painful)
Slit lamp findings	13 weeks	The secondary efficacy endpoint is the assessment of the rate of any Slit Lamp Findings \> Grade 2.; The subject will be instructed to take off the study lenses before the slit-lamp biomicroscopy assessment.; Slit-lamp biomicroscopy will be assessed according to the approved study biomicroscopy CRF.; ISO 11980:2012 Annex B will be used to grade the Slit-lamp findings.
Subject reported ocular complaints	13 weeks	Subjects will be asked to assess ocular complaints by using Study Diary.

Trial Locations

Locations (1)

ApexLens Co., Ltd.; 🇨🇳 Hsinchu, Taiwan